Analysis of the Efficacy and Safety of Semaglutide Combined with Metfor-min and Empagliflozin in the Treatment of Patients with Type 2 Diabetes Combined with Non-alcoholic Fatty Liver Disease
Objective To observe the clinical application value of semaglutide combined with metformin and empa-gliflozin in the treatment of patients with Type 2 Diabetes Mellitus(T2DM)combined with Non-Alcoholic Fatty Liver Disease(NAFLD).Methods A total of 100 patients with T2DM complicated with NAFLD admitted to Sijing Hospital of Songjiang District of Shanghai from May 2022 to May 2023 were selected as the study objects and divided into two groups with 50 cases each by drawing lots.The control group was given metformin empagliflozin,and the observation group was given semaglutide on the basis of the control group.The blood glucose,liver function,blood lipid and ad-verse reactions were compared between the two groups.Results The levels of fasting blood glucose,2-hour postpran-dial blood glucose,alanine aminotransferase,aspartate aminotransferase,glutamyl transpeptidase,total cholesterol and triglyceride in the observation group were lower than those in the control group,and the differences were statistically significant(all P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Metformin empagliflozin combined with semaglutide can regulate abnormal glu-cose and lipid metabolism and improve liver function in patients with T2DM combined with NAFLD,and is safe and reliable.
Type 2 diabetesNon-alcoholic fatty liver diseaseMetformin empagliflozinSemaglutide
维普
万方数据
